In vitro studies demonstrated a reduced incidence of apoptosis in patients administered inhaled anesthetics compared with those administered propofol during surgery.
New research findings by University College Dublin scientists published in the British Journal of Anaesthesia indicate that the type of anaesthetic used during surgery could affect the metastatic potential of cancer cells - that is their ability to spread to other parts of the body.
To conduct the research, the scientists took blood before and after surgery from breast cancer patients who had been given different types of anaesthetic and pain relief. Some of the women had used standard inhaled general anaesthetics with morphine based pain relief*(2), and others had been anaesthetised using regional (breast numbing) techniques with a single intravenous general anaesthetic called propofol to minimize morphine dosing*(3). In laboratory conditions, breast cancer cells were then exposed to these blood samples.
The scientists found that the blood from patients who had been given standard inhaled general anaesthetics with morphine pain relief reduced a process known as “apoptosis” whereby the body’s cells naturally die off. “Apoptosis” is crucial to preventing the metastatic spread of cancer. In contrast, cancer cells exposed to blood from patients who had been given regional anaesthesia and propofol showed a higher rate of apoptosis, or natural death of cancer cells.
Press release: http://bit.ly/1yi1UfC
Source: University College Dublin
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More